## **ForPatients**

by Roche

Neuromyelitis Optica Neuromyelitis optica spectrum disorders

## Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Trial Status Trial Runs In Trial Identifier
Completed 11 Countries NCT02028884 2013-003752-21,
SA-307JG BN40898

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

## Trial Summary:

The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with NMO and NMOSD.

Hoffmann-La Roche Sponsor	Phase 3 Phase	
NCT02028884 2013-003752-21, SA-307JG BN40898 Trial Identifiers		
Eligibility Criteria:		
Gender All	Age >=12 Years & <= 74 Years	Healthy Volunteers